FLGT 📈 Fulgent Genetics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3596641098
FLGT: Genetic Tests, Diagnostic Solutions, Cancer Therapies, DNA Analysis
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California. Web URL: https://www.fulgentgenetics.com
Additional Sources for FLGT Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
FLGT Stock Overview
Market Cap in USD | 614m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2016-09-29 |
FLGT Stock Ratings
Growth 5y | -10.3% |
Fundamental | -29.8% |
Dividend | - |
Rel. Strength Industry | -799 |
Analysts | 3.33/5 |
Fair Price Momentum | 15.23 USD |
Fair Price DCF | 2.86 USD |
FLGT Dividends
No Dividends PaidFLGT Growth Ratios
Growth Correlation 3m | -49.8% |
Growth Correlation 12m | -66.3% |
Growth Correlation 5y | -24.8% |
CAGR 5y | 4.25% |
CAGR/Mean DD 5y | 0.07 |
Sharpe Ratio 12m | -1.21 |
Alpha | -80.94 |
Beta | 1.73 |
Volatility | 48.41% |
Current Volume | 839.2k |
Average Volume 20d | 298k |
What is the price of FLGT stocks?
As of December 22, 2024, the stock is trading at USD 18.34 with a total of 839,154 shares traded.
Over the past week, the price has changed by -6.33%, over one month by +6.13%, over three months by -16.56% and over the past year by -35.94%.
As of December 22, 2024, the stock is trading at USD 18.34 with a total of 839,154 shares traded.
Over the past week, the price has changed by -6.33%, over one month by +6.13%, over three months by -16.56% and over the past year by -35.94%.
Is Fulgent Genetics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Fulgent Genetics (NASDAQ:FLGT) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -29.84 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FLGT as of December 2024 is 15.23. This means that FLGT is currently overvalued and has a potential downside of -16.96%.
Probably not. Based on ValueRay Fundamental Analyses, Fulgent Genetics (NASDAQ:FLGT) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -29.84 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FLGT as of December 2024 is 15.23. This means that FLGT is currently overvalued and has a potential downside of -16.96%.
Is FLGT a buy, sell or hold?
Fulgent Genetics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold FLGT.
Fulgent Genetics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold FLGT.
- Strong Buy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecast for FLGT stock price target?
According to ValueRays Forecast Model, FLGT Fulgent Genetics will be worth about 17.3 in December 2025. The stock is currently trading at 18.34. This means that the stock has a potential downside of -5.62%.
According to ValueRays Forecast Model, FLGT Fulgent Genetics will be worth about 17.3 in December 2025. The stock is currently trading at 18.34. This means that the stock has a potential downside of -5.62%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 27.7 | 50.9% |
Analysts Target Price | 36.5 | 99% |
ValueRay Target Price | 17.3 | -5.6% |